Screener
Vertex Pharmaceuticals VRTX ALYFTREK — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's ALYFTREK — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported ALYFTREK — product revenues, net of $573.6M in Q2 2026.
- How has Vertex Pharmaceuticals's ALYFTREK — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's ALYFTREK — product revenues, net increased by 265.8% year-over-year, from $156.8M to $573.6M.
- What does ALYFTREK — product revenues, net mean?
- This metric represents the total net sales generated from the specific pharmaceutical product or therapeutic line after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of market adoption and commercial success for this specific asset within the company's broader portfolio. Tracking this revenue stream helps investors assess the growth trajectory and commercial viability of the product in its target therapeutic area.
Ask your AI about Vertex Pharmaceuticals's alyftrek — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude